5 research outputs found

    Platinum Nanoparticles Supported on Reduced Graphite Oxide as Hydrogenation Catalyst

    Get PDF
    Platinum nanoparticles supported on reduced graphite oxide are produced by reduction of a slurry including graphite oxide and H2PtCl6·xH2O, and pyridine as modifying agent. Four compounds as a formation formateion decene-1 and nitrobenzene hydrogenation at hydrogen atmospheric pressure and 45°C. In the result of reduction Pt4+ is converted to Pt metal and graphite oxide loses of oxygen. The symbasis Pt loading with C/O ratio is observed. Compositions Pt - reduced graphite oxide catalyze the hudrogenation of decene-1 and nitrobenzene in a solution. The greatest activity is shown composition reduced by sodium borohydride with the particle size of 2.0 nm, however it is substantially lower than it for Pt/fullerene black catalyst. Some inhibiton of hydrogenation by incompletely reduced graphite oxide is shown. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/3505

    Exchange charge model of crystal field for 3d ions

    No full text

    Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry

    No full text
    Background: Physicians' adherence to guideline-recommended therapy is associated with short-term clinical outcomes in heart failure (HF) with reduced ejection fraction (HFrEF). However, its impact on longer-term outcomes is poorly documented. Here, we present results from the 18-month follow-up of the QUALIFY registry. Methods and results: Data at 18 months were available for 6118 ambulatory HFrEF patients from this international prospective observational survey. Adherence was measured as a continuous variable, ranging from 0 to 1, and was assessed for five classes of recommended HF medications and dosages. Most deaths were cardiovascular (CV) (228/394) and HF-related (191/394) and the same was true for unplanned hospitalizations (1175 CV and 861 HF-related hospitalizations, out of a total of 1541). According to univariable analysis, CV and HF deaths were significantly associated with physician adherence to guidelines. In multivariable analysis, HF death was associated with adherence level [subdistribution hazard ratio (SHR) 0.93, 95% confidence interval (CI) 0.87–0.99 per 0.1 unit adherence level increase; P = 0.034] as was composite of HF hospitalization or CV death (SHR 0.97, 95% CI 0.94–0.99 per 0.1 unit adherence level increase; P = 0.043), whereas unplanned all-cause, CV or HF hospitalizations were not (all-cause: SHR 0.99, 95% CI 0.9–1.02; CV: SHR 0.98, 95% CI 0.96–1.01; and HF: SHR 0.99, 95% CI 0.96–1.02 per 0.1 unit change in adherence score; P = 0.52, P = 0.2, and P = 0.4, respectively). Conclusion: These results suggest that physicians' adherence to guideline-recommended HF therapies is associated with improved outcomes in HFrEF. Practical strategies should be established to improve physicians' adherence to guidelines. © 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiolog
    corecore